GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Restart Life Sciences Corp (OTCPK:NMLSF) » Definitions » Cyclically Adjusted PS Ratio

NMLSF (Restart Life Sciences) Cyclically Adjusted PS Ratio : (As of May. 31, 2025)


View and export this data going back to 2013. Start your Free Trial

What is Restart Life Sciences Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Restart Life Sciences Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Restart Life Sciences's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Restart Life Sciences Cyclically Adjusted PS Ratio Chart

Restart Life Sciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 43.18 -

Restart Life Sciences Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 43.18 - - - -

Competitive Comparison of Restart Life Sciences's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Restart Life Sciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Restart Life Sciences's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Restart Life Sciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Restart Life Sciences's Cyclically Adjusted PS Ratio falls into.


;
;

Restart Life Sciences Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Restart Life Sciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2024 is calculated as:

For example, Restart Life Sciences's adjusted Revenue per Share data for the three months ended in Dec. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=0/127.3637*127.3637
=0.000

Current CPI (Dec. 2024) = 127.3637.

Restart Life Sciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201503 0.000 99.789 0.000
201506 0.000 100.500 0.000
201509 0.000 100.421 0.000
201512 0.000 99.947 0.000
201603 0.000 101.054 0.000
201606 0.000 102.002 0.000
201609 0.000 101.765 0.000
201612 0.000 101.449 0.000
201703 0.000 102.634 0.000
201706 0.000 103.029 0.000
201709 0.000 103.345 0.000
201712 0.000 103.345 0.000
201803 0.000 105.004 0.000
201806 0.000 105.557 0.000
201809 0.000 105.636 0.000
201812 0.000 105.399 0.000
201903 0.000 106.979 0.000
201906 0.000 107.690 0.000
201909 0.000 107.611 0.000
201912 0.002 107.769 0.002
202003 0.002 107.927 0.002
202006 0.000 108.401 0.000
202009 0.000 108.164 0.000
202012 0.000 108.559 0.000
202103 0.000 110.298 0.000
202106 0.000 111.720 0.000
202109 0.000 112.905 0.000
202112 0.000 113.774 0.000
202203 0.000 117.646 0.000
202206 0.000 120.806 0.000
202209 0.000 120.648 0.000
202212 0.000 120.964 0.000
202303 0.000 122.702 0.000
202306 0.000 124.203 0.000
202309 0.001 125.230 0.001
202312 -0.001 125.072 -0.001
202403 0.000 126.258 0.000
202406 0.000 127.522 0.000
202409 0.000 127.285 0.000
202412 0.000 127.364 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Restart Life Sciences  (OTCPK:NMLSF) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Restart Life Sciences Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Restart Life Sciences's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Restart Life Sciences Business Description

Traded in Other Exchanges
Address
700 - 838 West Hastings Street, Vancouver, BC, CAN, V6C 0A6
Restart Life Sciences Corp is a Canadian life sciences company dedicated to addressing today's health challenges with wellness solutions. Its focus is on creating health foods that address the needs of this community. Its flagship developments include natural remedies for individuals on the Autism Spectrum, Specialty Health Foods, Psilocybin Clinical Trial for Fragile X Syndrome, and Orphan Drug Designation (FDA and EMA). The company operates in one industry segment, being research and development of psilocybin, and in one geographic area, being Canada.

Restart Life Sciences Headlines

From GuruFocus

U.S. FDA Approves Nova Mentis Orphan Drug Application

By PRNewswire PRNewswire 11-02-2021

Nova Mentis Begins Enrollment in North American Autism Study

By PRNewswire PRNewswire 03-23-2022